Dabigatran may increase the risk of heart attack

File:AMI scheme.png

Dabigatran was one of the saviours of modern medicine, thought to be the end of warfarin’s reign on anticoagulation, a safer option with less monitoring. Within a few short years it went from proven trial to the shelves – but the adverse events are now being revealed.

Uchino and Hernandez have released a meta-analysis that’s burning through the internet wires, in the Archives of Internal Medicine. This meta-analysis combines seven different articles, with over 30,000 patients, and found a HR of around 1.27-1.3 for coronary events.

Perhaps another randomised controlled trial will be required here to put this to bed – after all, this drug is going to be used in people who may be at cardiac risk anyway, one that doesn’t need to be compounded. Of course, further study will be required for the pharmacological mechanism as well.

Read the original article here.


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s